Jan 13 (Reuters) - Oric Pharmaceuticals Inc :
* ORIC PHARMACEUTICALS ANNOUNCES CLINICAL SUPPLY AGREEMENT TO EVALUATE ORIC-114 IN COMBINATION WITH AMIVANTAMAB FOR THE FIRST-LINE TREATMENT OF NSCLC WITH EGFR EXON 20 INSERTION MUTATIONS
* ORIC PHARMACEUTICALS INC - ENTERS SUPPLY AGREEMENT WITH JANSSEN TO EVALUATE ORIC-114
* ORIC PHARMACEUTICALS INC - TO CONDUCT AND SPONSOR TRIAL; J&J TO PROVIDE SC AMIVANTAMAB
* ORIC PHARMACEUTICALS INC - TO INITIATE PHASE 1B TRIAL FOR ORIC-114 IN Q1 2025
* ORIC PHARMACEUTICALS INC - EXPECTS TO REPORT INITIAL TRIAL DATA IN MID-2026
Source text: Further company coverage:
((Reuters.Briefs@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.